BIOANALYTICAL TESTING

Analytical services for pre-clinical studies up through Phase III, including statistical evaluation.
Comprising experienced experts, our team has completed more than 600 bio-studies for pharmaceutical companies, across Europe, the United States, Asia and Australia.

Overview

Most activities of the Bioanalytical department, which collaborates with the Clinical department of the company, are focused on conducting complete bioequivalence studies (including clinical, analytical, pharmacokinetic and statistical part) as well as the analyses of diagnostic biomarkers.

The Bioanalytical department comprises a team of experienced analysts and laboratory technicians. The laboratories are equipped with nine modern LC/MS/MS devices with triple quadrupoles, six of which being additionally equipped with a 2-channel HPLC system. The capacity of the Bioanalytical department is up to 3,750 analyses of biological samples per day (including calibration and QC samples and depending on the complexity of the analyses).

Development and validation of bioanalytical methods

Bioanalytical methods are developed and validated in accordance with GLP rules and ICH/FDA and EMEA guidelines. So far, over 300 methods have been developed and validated in the company. Please see below for a full list of our bioanalytical methods, and if you don’t find what you’re looking for please contact us.

PK/TK studies on animals

In the area of ​​pre-clinical evaluation of active ingredients in animals, the Bioanalytical department cooperates with partners in the Czech Republic as well as in the world and conducts its own toxicological and pharmacokinetic studies.

During these activities, Quinta provides complete analytical support comprising inspections of the quality of the application forms, analyses of the studied active ingredients and metabolites in the collected biological samples. Quinta also performs the subsequent toxicokinetic and pharmacokinetic evaluations.

Analyses of drugs and their metabolites

Within clinical trials in different phases, the Bioanalytical department cooperates with the Clinical department of Quinta as well as with external clinics in the world that conduct their own PK/PD and BA/BE studies.

The Bioanalytical department provides a complete analytical support from the preparation of protocols, through the development and validation of bioanalytical methods, preparation of the sampling manuals for clinical workplaces, analyses of the studied active ingredients and/or metabolites in the collected biological samples to the pharmacokinetic and statistical evaluation of the studies.

Determination of structure of metabolites

In addition to its own Clinical department in the company, the Bioanalytical department cooperates with many clinics involved in Phase I clinical trials. Highly trained and experienced employees also take part in determining the structure of metabolites and their isolation from biological matrices.

Biostatistic evaluation

We perform calculations of pharmacokinetic parameters and statistical evaluation of the results of studies results using specialized software:

  • SAS®    (SAS Institute Inc.,www.sas.com)
  • WinNonlin®    Professional (Pharsight Corporation, www.pharsight.com)

Services offered:

  • displaying graphs of pharmacokinetic profiles (mean, individual, overlay of all the subjects for the given type of treatment, etc.)
  • calculation of pharmacokinetic parameters (non-compartmental model)
    • single dose: AUC0-t     , AUC0-¥      , Cmax , Tmax        , λz   , T1/2
    • steady-state: AUCτ   , Cmax,ss           , Cmin,ss           , Tmax,ss           , Fluctuation
  • statistical evaluation of bioequivalence – average bioequivalence (parallel design, 2×2 crossover design, replicative 2-treatment 4-period design, etc.)
  • multi-dimensional ANOVA – mixed model (log-transformed data, un-transformed data), LS-means, residual variability, within subject variability, etc.
  • hypothesis testing (Schuirmann)
  • power of tests (power of ANOVA – multiplicative model)
  • non-parametric tests (non-parametric ANOVA)
  • calculation of other pharmacokinetic parameters according to the requirements of the customer, e.g. Langmuir model (in-vitro bioequivalence),
  • calculation of bioavailability (absolute, relative bioavailability)
  • pharmacokinetic / toxicokinetic evaluation (accumulation, dose-proportionality, etc.)
  • descriptive statistics, confidence interval, outlying value ​​tests
  • statistical significance of the observed influences – influence of the dosage form, diet, sex, age, etc.
  • compartmental modeling (WinNonlin)
  • and other calculations according to the requirements of the customer
Validated Bioanalytical Methods

Code

Analyte

Method

LLOQ
(ng/mL)

Note

Code:

1

Analyte:

11-Deoxycortisol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.02

Note:

determination of endogenous levels in postmenopausal women

Code:

2

Analyte:

17-Carboxybudesonide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

in dog plasma

Code:

3

Analyte:

17-Deacetylnorgestimate

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.02

Note:

Code:

4

Analyte:

17-Hydroxyprogesterone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.02

Note:

determination of endogenous levels in postmenopausal women

Code:

5

Analyte:

1-Adamantylethyloxy-3-morpholino-2-propanol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

Code:

6

Analyte:

2-Hydroxymethylmetronidazole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

4

Note:

Code:

7

Analyte:

4-Methylaminoantipyrine (MAA)

Method:

HPLC/MS/MS

LLOQ (ng/mL):

100

Note:

main metabolite of Metamizole

Code:

8

Analyte:

5′-Deoxy-5-fluorocytidine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

25

Note:

Code:

9

Analyte:

5′-Deoxy-5-fluorouridine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

25

Note:

Code:

10

Analyte:

5-Fluorouracil

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

11

Analyte:

5-Hydroxymethyltolterodine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

Code:

12

Analyte:

5-Hydroxypropafenone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

13

Analyte:

9-Hydroxyrisperidone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code

Analyte

Method

LLOQ
(ng/mL)

Note

Code:

14

Analyte:

Abiraterone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

15

Analyte:

Acetaminophen (paracetamol)

Method:

HPLC/MS/MS

LLOQ (ng/mL):

250

Note:

Code:

16

Analyte:

Acetazolamide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

250

Note:

Code:

17

Analyte:

Acetylsalicylic acid

Method:

HPLC/MS/MS

LLOQ (ng/mL):

25

Note:

common method with salicylic acid

Code:

18

Analyte:

Acetylsalicylic acid

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

common method with salicylic acid

Code:

19

Analyte:

Aciclovir

Method:

HPLC

LLOQ (ng/mL):

15

Note:

Code:

20

Analyte:

Aciclovir

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

21

Analyte:

Agomelatine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

22

Analyte:

Aldosterone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.01

Note:

determination of endogenous levels in postmenopausal women

Code:

23

Analyte:

Alendronate

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.75

Note:

Code:

24

Analyte:

Amlodipine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

25

Analyte:

Amlodipine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

rat plasma direct injection

Code:

26

Analyte:

Amlodipine

Method:

chiral HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

27

Analyte:

Anagrelide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.075

Note:

Code:

28

Analyte:

Anastrozole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

29

Analyte:

Androstenedione

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.02

Note:

determination of endogenous levels in postmenopausal women

Code:

30

Analyte:

Aripiprazene

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

31

Analyte:

Aripiprazole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.4

Note:

Code:

32

Analyte:

Atomoxetine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

33

Analyte:

Atorvastatin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.8

Note:

common method with ezetimibe

Code:

34

Analyte:

Atorvastatin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

35

Analyte:

Azithromycin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

4

Note:

Code:

36

Analyte:

Bendroflumethiazide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.4

Note:

Code:

37

Analyte:

Bicalutamide

Method:

chiral HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

38

Analyte:

Bicalutamide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

39

Analyte:

Bisoprolol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

40

Analyte:

Bosentan

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

41

Analyte:

Budesonide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

in dog plasma

Code:

42

Analyte:

Bumetanide

Method:

HPLC

LLOQ (ng/mL):

4

Note:

Code:

43

Analyte:

Caffeine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

100

Note:

common method with paraxantine

Code:

44

Analyte:

Candesartan

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

45

Analyte:

Capecitabine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

100

Note:

Code:

46

Analyte:

Captopril (free)

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

47

Analyte:

Captopril (free)

Method:

HPLC

LLOQ (ng/mL):

15

Note:

Code:

48

Analyte:

Carbamazepine

Method:

HPLC

LLOQ (ng/mL):

25

Note:

Code:

49

Analyte:

Carvedilol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

50

Analyte:

Carvedilol metabolite M IV

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

51

Analyte:

Cefditoren

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

52

Analyte:

Cefprozil

Method:

HPLC/MS/MS

LLOQ (ng/mL):

100

Note:

Code:

53

Analyte:

Cefuroxime

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

54

Analyte:

Celecoxib

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

Code:

55

Analyte:

Chlorambucil

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

56

Analyte:

Chlorthalidone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

57

Analyte:

Cilostazol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

58

Analyte:

Ciprofloxacine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

59

Analyte:

Clobazam

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

60

Analyte:

Clozapin

Method:

GC/MS

LLOQ (ng/mL):

0.6

Note:

Code:

61

Analyte:

Dapagliflozin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

common method with linagliptin

Code:

62

Analyte:

Dasatinib

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

Code:

63

Analyte:

Desethyloxybutynin

Method:

GC/MS

LLOQ (ng/mL):

2

Note:

Code:

64

Analyte:

Desethyloxybutynin

Method:

HPLC

LLOQ (ng/mL):

4

Note:

Code:

65

Analyte:

Desloratadine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

Code:

66

Analyte:

Desmethylfluoxetine

Method:

GC/MS

LLOQ (ng/mL):

0.4

Note:

Code:

67

Analyte:

Dexamethasone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

Code:

68

Analyte:

Dexketoprofen

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

69

Analyte:

Diclofenac

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

70

Analyte:

Diosmetin-3-O-glucuronide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

Code:

71

Analyte:

Donepezil

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

72

Analyte:

Doxazosin

Method:

HPLC

LLOQ (ng/mL):

0.4

Note:

Code:

73

Analyte:

Drospirenone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

74

Analyte:

Drotaverine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

3

Note:

Code:

75

Analyte:

Duloxetine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

76

Analyte:

Emoxipine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

77

Analyte:

Enalapril

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

78

Analyte:

Enalaprilat

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1.2

Note:

Code:

79

Analyte:

Entecavir

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

Code:

80

Analyte:

Eplerenon

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

Code:

81

Analyte:

Epoxycarbamazepin

Method:

HPLC

LLOQ (ng/mL):

25

Note:

Code:

82

Analyte:

Erlotinib

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

83

Analyte:

Escitalopram

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

Code:

84

Analyte:

Esomeprazole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

Code:

85

Analyte:

Estradiol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.0008

Note:

determination of endogenous levels in postmenopausal women

Code:

86

Analyte:

Estrone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.001

Note:

determination of endogenous levels in postmenopausal women

Code:

87

Analyte:

Estrone sulfate

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.01

Note:

determination of endogenous levels in postmenopausal women

Code:

88

Analyte:

Eszopiclon

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

Code:

89

Analyte:

Ethinylestradiol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.001

Note:

Code:

90

Analyte:

Everolimus

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

in whole blood

Code:

91

Analyte:

Exemestane

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

Code:

92

Analyte:

Ezetimibe

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.04

Note:

common method with ezetimibe glucuronide

Code:

93

Analyte:

Ezetimibe

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.08

Note:

common method with atorvastatin

Code:

94

Analyte:

Ezetimibe

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

common method with simvastatin

Code:

95

Analyte:

Ezetimibe glucuronide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.8

Note:

common method with ezetimibe

Code:

96

Analyte:

Ezetimibe glucuronide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.8

Note:

common method with atorvastatin

Code

Analyte

Method

LLOQ
(ng/mL)

Note

Code:

97

Analyte:

Famotidine

Method:

HPLC

LLOQ (ng/mL):

2.5

Note:

Code:

98

Analyte:

Fenpiverinium

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.03

Note:

common method with ketorolac and pitofenone

Code:

99

Analyte:

Fenspiride

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

100

Analyte:

Fingolimod

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.01

Note:

in whole blood

Code:

101

Analyte:

Fluoxetine

Method:

GC/MS

LLOQ (ng/mL):

0.4

Note:

Code:

102

Analyte:

Flupirtine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

20

Note:

Code:

103

Analyte:

Flurbiprofen

Method:

HPLC/MS/MS

LLOQ (ng/mL):

100

Note:

Code:

104

Analyte:

Fluvoxamine

Method:

HPLC

LLOQ (ng/mL):

1.5

Note:

Code:

105

Analyte:

Furagin (Furazidine)

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

106

Analyte:

Ganciclovir

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

107

Analyte:

Gentamicin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

Note:

in animals samples

Code:

108

Analyte:

Gliclazide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

20

Note:

Code:

109

Analyte:

Glimepiride

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

110

Analyte:

Glycoursodeoxycholic acid

Method:

HPLC/MS/MS

LLOQ (ng/mL):

20

Note:

endogenous compound

Code:

111

Analyte:

Hydrochlorothiazide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

112

Analyte:

Hydrocortisone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

endogenous compound

Code:

113

Analyte:

Hydroxyurea

Method:

HPLC/MS/MS

LLOQ (ng/mL):

250

Note:

Code:

114

Analyte:

Ibuprofen

Method:

HPLC/MS/MS

LLOQ (ng/mL):

500

Note:

Code:

115

Analyte:

Imatinib

Method:

HPLC/MS/MS

LLOQ (ng/mL):

20

Note:

Code:

116

Analyte:

Indapamide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

in whole blood

Code:

117

Analyte:

Ipidacrine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

118

Analyte:

Irbesartan

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

119

Analyte:

Isoprinosine (DIP)

Method:

HPLC/MS/MS

LLOQ (ng/mL):

80

Note:

Code:

120

Analyte:

Isoprinosine (PAcBA)

Method:

HPLC/MS/MS

LLOQ (ng/mL):

200

Note:

Code:

121

Analyte:

Ivabradine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

Code

Analyte

Method

LLOQ
(ng/mL)

Note

Code:

122

Analyte:

Ketorolac

Method:

HPLC/MS/MS

LLOQ (ng/mL):

3

Note:

common method with fenpiverinium and pitofenone

Code:

123

Analyte:

Lacidipine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.02

Note:

Code:

124

Analyte:

Lenalidomide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

125

Analyte:

Letrozole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

126

Analyte:

Letrozole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

127

Analyte:

Levetiracetam

Method:

HPLC/MS/MS

LLOQ (ng/mL):

200

Note:

Code:

128

Analyte:

Levocetirizine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2.5

Note:

Code:

129

Analyte:

Levocetirizine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

common method with montelucast

Code:

130

Analyte:

Levothyroxine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

endogenous compound

Code:

131

Analyte:

Linagliptin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

common method with dapagliflozin

Code:

132

Analyte:

Linezolid

Method:

HPLC/MS/MS

LLOQ (ng/mL):

200

Note:

Code:

133

Analyte:

Liothyronine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

endogenous compound

Code:

134

Analyte:

Lisinopril

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

135

Analyte:

Losartan

Method:

HPLC/MS/MS

LLOQ (ng/mL):

3

Note:

Code:

136

Analyte:

Lovastatin

Method:

GC/MS/MS

LLOQ (ng/mL):

0.15

Note:

Code:

137

Analyte:

Lovastatin hydroxyacid

Method:

GC/MS/MS

LLOQ (ng/mL):

0.15

Note:

Code:

138

Analyte:

Megestrol acetate

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

139

Analyte:

Meloxicam

Method:

HPLC

LLOQ (ng/mL):

30

Note:

Code:

140

Analyte:

Memantine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

141

Analyte:

Metformin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

Code:

142

Analyte:

Methylsulfoxyethanol (MSE)

Method:

HPLC/MS/MS

LLOQ (ng/mL):

200

Note:

Code:

143

Analyte:

Metoprolol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

144

Analyte:

Metronidazole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

20

Note:

Code:

145

Analyte:

Mianserin

Method:

chiral HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

146

Analyte:

Mildronate

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

147

Analyte:

Milnacipran

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

148

Analyte:

Moclobemide

Method:

HPLC

LLOQ (ng/mL):

30

Note:

Code:

149

Analyte:

Montelukast

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

150

Analyte:

Montelukast

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

common method with levocetirizine

Code:

151

Analyte:

Moxifloxacin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

152

Analyte:

Naftidrofuryl

Method:

HPLC

LLOQ (ng/mL):

200

Note:

Code:

153

Analyte:

Naproxen

Method:

HPLC/MS/MS

LLOQ (ng/mL):

200

Note:

Code:

154

Analyte:

Naproxen

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

in urine

Code:

155

Analyte:

Nebivolol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.02

Note:

Code:

156

Analyte:

Nerofe

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1,000.00

Note:

in dog plasma

Code:

157

Analyte:

Nitrofurantoin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

158

Analyte:

Norgestimate

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.0004

Note:

Code:

159

Analyte:

O-desmethyltramadol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

160

Analyte:

O-desmethylvenlafaxine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

161

Analyte:

O-hydroxyatorvastatin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.4

Note:

common method with ezetimibe

Code:

162

Analyte:

Olanzapine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

163

Analyte:

Olanzapine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

Code:

164

Analyte:

Olmesartan

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

Code:

165

Analyte:

Omeprazole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

Code:

166

Analyte:

Ondansetron

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

167

Analyte:

Oracin

Method:

HPLC

LLOQ (ng/mL):

20

Note:

Code:

168

Analyte:

Ornidazole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

200

Note:

Code:

169

Analyte:

Oseltamivir

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

170

Analyte:

Oxybutynin

Method:

GC/MS

LLOQ (ng/mL):

0.2

Note:

Code

Analyte

Method

LLOQ
(ng/mL)

Note

Code:

171

Analyte:

Paliperidon

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

172

Analyte:

Paraxantine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

100

Note:

common method with caffeine

Code:

173

Analyte:

Paroxetine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

174

Analyte:

Paroxetine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.025

Note:

Code:

175

Analyte:

Paroxetine metabolite

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

176

Analyte:

Pazopanib

Method:

HPLC/MS/MS

LLOQ (ng/mL):

100

Note:

Code:

177

Analyte:

Pentoxifylline

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

178

Analyte:

Pentoxifylline metabolite M1

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

179

Analyte:

Pentoxifylline metabolite M5

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

Code:

180

Analyte:

Perindopril

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2.5

Note:

common method with perindoprilate

Code:

181

Analyte:

Perindoprilate

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

common method with perindopril

Code:

182

Analyte:

p-hydroxy atorvastatin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.04

Note:

common method with ezetimibe

Code:

183

Analyte:

Pioglitazone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

Code:

184

Analyte:

Pioglitazone metabolite M IV

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

185

Analyte:

Pitofenone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

common method with ketorolac and fenpiverinium

Code:

186

Analyte:

Pizotifen

Method:

GC/MS/MS

LLOQ (ng/mL):

0.05

Note:

Code:

187

Analyte:

Pramipexole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.02

Note:

Code:

188

Analyte:

Prednisolone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

3

Note:

Code:

189

Analyte:

Pregabalin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

190

Analyte:

Pridinol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

191

Analyte:

Pridinol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

in urine

Code:

192

Analyte:

Propafenone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

193

Analyte:

Propiverine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

194

Analyte:

Quetiapine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

195

Analyte:

Raloxifene

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.01

Note:

Code:

196

Analyte:

Raloxifene-4-glucoronide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

197

Analyte:

Raloxifene-6-glucoronide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

198

Analyte:

Ramipril

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

199

Analyte:

Ramipril

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.4

Note:

common method with ramiprilate

Code:

200

Analyte:

Ramipril

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

in dog plasma

Code:

201

Analyte:

Ramiprilate

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

common method with ramipril

Code:

202

Analyte:

Ramiprilate

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

in dog plasma

Code:

203

Analyte:

Ranitidin

Method:

HPLC

LLOQ (ng/mL):

10

Note:

Code:

204

Analyte:

Ranolazine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

25

Note:

Code:

205

Analyte:

Rasagiline

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

206

Analyte:

Ribavirin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

3

Note:

Code:

207

Analyte:

Risperidone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

208

Analyte:

Ritonavir

Method:

HPLC/MS/MS

LLOQ (ng/mL):

20

Note:

Code:

209

Analyte:

Rizatriptan

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

210

Analyte:

Ropinirole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

211

Analyte:

Rosuvastatin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

Code:

212

Analyte:

Salicylic acid

Method:

HPLC

LLOQ (ng/mL):

200

Note:

Code:

213

Analyte:

Salicylic acid

Method:

HPLC/MS/MS

LLOQ (ng/mL):

100

Note:

common method with acetylsalicylic acid

Code:

214

Analyte:

Salicylic acid

Method:

HPLC/MS/MS

LLOQ (ng/mL):

20

Note:

common method with acetylsalicylic acid

Code:

215

Analyte:

Sildenafil

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

216

Analyte:

Sildenafil

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

217

Analyte:

Simvastatin

Method:

GC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

218

Analyte:

Simvastatin

Method:

LC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

219

Analyte:

Simvastatin

Method:

LC/MS/MS

LLOQ (ng/mL):

0.2

Note:

common method with ezetimibe

Code:

220

Analyte:

Simvastatin

Method:

LC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

221

Analyte:

Simvastatin hydroxyacid

Method:

GC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

222

Analyte:

Simvastatin hydroxyacid

Method:

LC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

223

Analyte:

Simvastatin hydroxyacid

Method:

LC/MS/MS

LLOQ (ng/mL):

0.05

Note:

common method with ezetimibe

Code:

224

Analyte:

Sitagliptin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

225

Analyte:

Solifenacin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

226

Analyte:

Tadalafil

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

227

Analyte:

Tamsulosin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

228

Analyte:

Tamsulosin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.1

Note:

Code:

229

Analyte:

Tamsulosin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

Code:

230

Analyte:

Tauroursodeoxycholic acid

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

endogenous compound

Code:

231

Analyte:

Telmisartan

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

232

Analyte:

Tenofovir

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

233

Analyte:

Terbinafine

Method:

HPLC

LLOQ (ng/mL):

20

Note:

Code:

234

Analyte:

Thiocolchicoside metabolite M1

Method:

HPLC/MS/MS

LLOQ (ng/mL):

1

Note:

Code:

235

Analyte:

Tianeptine

Method:

chiral HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

236

Analyte:

Ticagrelor

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

237

Analyte:

Tiotropium

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.0001

Note:

Code:

238

Analyte:

Tolperisone

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

239

Analyte:

Tolterodine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.05

Note:

Code:

240

Analyte:

Torasemide

Method:

HPLC/MS/MS

LLOQ (ng/mL):

20

Note:

Code:

241

Analyte:

Toremifene

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

242

Analyte:

Tramadol

Method:

GC/MS

LLOQ (ng/mL):

6

Note:

Code:

243

Analyte:

Tramadol

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

244

Analyte:

Trimetazidine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code

Analyte

Method

LLOQ
(ng/mL)

Note

Code:

245

Analyte:

Ulipristal

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.2

Note:

Code:

246

Analyte:

Uridine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

150

Note:

endogenous compound

Code:

247

Analyte:

Ursodeoxycholic acid

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

endogenous compound

Code:

248

Analyte:

Valganciclovir

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

249

Analyte:

Valproic acid

Method:

HPLC/MS/MS

LLOQ (ng/mL):

250

Note:

Code:

250

Analyte:

Valsartan

Method:

HPLC/MS/MS

LLOQ (ng/mL):

50

Note:

Code:

251

Analyte:

Vardenafil

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.25

Note:

Code:

252

Analyte:

Venlafaxine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

10

Note:

in rat plasma

Code:

253

Analyte:

Venlafaxine

Method:

HPLC/MS/MS

LLOQ (ng/mL):

0.5

Note:

Code:

254

Analyte:

Vildagliptin

Method:

HPLC/MS/MS

LLOQ (ng/mL):

2

Note:

Code:

255

Analyte:

Voriconazole

Method:

HPLC/MS/MS

LLOQ (ng/mL):

5

Note:

Code:

256

Analyte:

Warfarin

Method:

HPLC

LLOQ (ng/mL):

20

Note:

Code:

257

Analyte:

Zolpidem

Method:

HPLC

LLOQ (ng/mL):

1

Note:

plasma direct injection

Code:

258

Analyte:

Zopiclon

Method:

HPLC

LLOQ (ng/mL):

4

Note:

Additional Services

API SOLUTIONS

Proudly based in Central Europe, with partners in the EU, US and Asia, Quinta has 250 experienced in-house professionals ready to support your projects.

More Info

NITROSAMINES ANALYSIS

Based on isotopically labeled standards, our customizable in-house detection methods are available immediately.

More Info

MONITORING OF STUDIES

Oversight of participant health and correctness of treatments during clinical studies.

PHARMACOVIGILANCE

Monitoring of daily routine to detect unrecognized adverse events, plus assess and ensure drug safety.

MODULE 3 AUDIT

Thorough dossier M3 data audit to ensure consistency and compliance with regulatory requirements.

IMPD COMPILATION

As an EU based company we are well-placed to help create & develop your IMPD.

AND MUCH MORE

It’s not an exhaustive list so if you don’t see what you need, contact us.

Questions?

Our Sales team is happy to help: sales@quinta.cz

More about Quinta

Your Complete Solution

Latest News & Events

Questions?

Please use the contact details or form below.

quinta@quinta.cz

+420 242 454 311

    For general and business contact only. To register as a volunteer for clinical studies (CZ nationals only) or speak with our clinical department, please visit here.